Kiniksa Pharmaceuticals International Plc () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?

20-Sep-2025

As of August 11, 2025, Kiniksa Pharmaceuticals International Plc's valuation has shifted from fair to attractive, indicating it may be undervalued despite a high P/E ratio of 565.79 and an EV to EBITDA ratio of 402.35, while outperforming the S&P 500 with an 81.60% year-to-date return.

Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?

20-Sep-2025

As of October 1, 2023, Kiniksa Pharmaceuticals is in a bullish technical position, with positive indicators across multiple time frames, and has significantly outperformed the S&P 500 year-to-date with an 81.60% return compared to 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Profit of 108.83%, the company declared Outstanding results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD 66.94 MM
DEBT-EQUITY RATIO (HY) Lowest at -60.2 %
NET SALES(Q) Highest at USD 156.8 MM

With ROE of 0.00%, it has a valuation with a 0.00 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,710 Million (Small Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.62

Return on Equity

-999,999.00%

Price to Book

5.47

Revenue and Profits:

Net Sales:

157 Million

(Quarterly Results - Jun 2025)

Net Profit:

18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.04%

6 Months

48.05%

1 Year

109.98%

2 Years

133.11%

3 Years

175.03%

4 Years

223.59%

5 Years

132.99%

Kiniksa Pharmaceuticals International Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60

Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.60 on October 24, 2025, highlighting its strong performance in the pharmaceuticals sector. The company reported a 44.61% return over the past year and impressive financial metrics, indicating solid operational health and growth potential.

Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12

Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 39.12 on October 1, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 54.56% return over the past year, significant net profit growth, and a solid balance sheet, showcasing its resilience in a competitive market.

Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97

Kiniksa Pharmaceuticals International Plc achieved a new 52-week high of USD 38.97 on September 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company reported a 52.30% return over the past year and impressive net profit growth of 108.83%, highlighting its operational strength.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

250.68%

EBIT Growth (5y)

15.28%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.79% vs 12.49% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 109.41% vs 195.51% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "156.80",
          "val2": "137.80",
          "chgp": "13.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20.50",
          "val2": "13.60",
          "chgp": "50.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.80",
          "val2": "8.50",
          "chgp": "109.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "128.60%",
          "val2": "96.30%",
          "chgp": "3.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 56.57% vs 22.75% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -406.38% vs -92.31% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "423.20",
          "val2": "270.30",
          "chgp": "56.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.90",
          "val2": "-23.10",
          "chgp": "-90.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.20",
          "val2": "14.10",
          "chgp": "-406.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-107.80%",
          "val2": "-93.20%",
          "chgp": "-1.46%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

156.80

137.80

13.79%

Operating Profit (PBDIT) excl Other Income

20.50

13.60

50.74%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

17.80

8.50

109.41%

Operating Profit Margin (Excl OI)

128.60%

96.30%

3.23%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 13.79% vs 12.49% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 109.41% vs 195.51% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

423.20

270.30

56.57%

Operating Profit (PBDIT) excl Other Income

-43.90

-23.10

-90.04%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-43.20

14.10

-406.38%

Operating Profit Margin (Excl OI)

-107.80%

-93.20%

-1.46%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 56.57% vs 22.75% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -406.38% vs -92.31% in Dec 2023

All Annual Results

Company CV

About

Company Coordinates

Company Details

Tel:

Registrar Details

Kiniksa Pharmaceuticals International Plc

1Day

52 Week

CASH

FII

DII

Promoter

Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?

Watch in Real-Time

Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

With a growth in Net Profit of 108.83%, the company declared Outstanding results in Jun 25

With ROE of 0.00%, it has a valuation with a 0.00 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60

Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12

Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About

Company Coordinates